The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...

Part of that spike is due to rising rates of cancers that affect primarily women, including breast cancer and endometrial ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

If somebody has gone through menopause and then bleeding reappears, it’s really important that the patient does not make ...

Cancer incidence continues to rise for many common cancers—especially for women. The incidence rate for women younger than 50 ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

Use of long-acting, reversible contraceptives is associated with an increased risk of certain cancers, a study suggests.

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of ...